MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Anxiety"

  • 2024 International Congress

    Tremor and dizziness in a psychiatric patient

    O. Toth-Basa, A. Centea, M. Bonea, L. Perju-Dumbrava (Cluj-Napoca, Romania)

    Objective: We want to report a case of a patient with anxiety whose neurological symptoms were due to a basal ganglia cavernous malformation. Background: Tremor…
  • 2024 International Congress

    Aberrant connectivity in Resting-State Brain Networks Underlying Neuropsychiatric Symptoms in Prodromal Lewy Body Dementia.

    L. Wright, P. Donaghy, D. Burn, J-P. Taylor, J. O'Brien, A. Yarnall, F. Matthews, M. Firbank, H. Sigurdsson, J. Schumacher, A. Thomas, R. Lawson (Newcastle upon Tyne, United Kingdom)

    Objective: This study aimed to determine the functional neural correlates of neuropsychiatric symptoms (NPS), including mood disorders, anxiety and psychosis, in prodromal Lewy body dementia (LBD)…
  • 2024 International Congress

    Opportunities for Medical Knowledge Self-Assessment in Movement Disorder Fellowship

    A. Higinbotham, A. Wang, A. Toth, C. Kilbane (Charlottesville, USA)

    Objective: To determine 1) what opportunities for medical knowledge self-assessment exist in movement disorder fellowship training, 2) how satisfied fellows are with such opportunities, and…
  • 2023 International Congress

    Psilocybin therapy for depression and anxiety associated with Parkinson’s disease: a pilot study (NCT04932434)

    E. Bradley, K. Sakai, G. Fernandes, C. Ludwig, M. Bock, J. Ostrem, C. Tanner, A. O'Donovan, P. Finley, Z. Busby, A. Mckernan, R. Zuzuarregui, A. Penn, A. Wang, A. Theberge, R. Rosen, J. Woolley (San Francisco, USA)

    Objective: To investigate the safety, tolerability, feasibility, and preliminary efficacy of moderate and high dose psilocybin treatment with psychotherapeutic support for comorbid Parkinson's disease (PD)…
  • 2023 International Congress

    The impact of anxiety symptoms and treatment on Parkinson’s disease-related disability: findings from the Parkinson’s Progression Markers Initiative

    N. Dahodwala, D. Weintraub, M. Bock, R. Cho, C. Caspell-Garcia, E. Brown, R. Dobkin (Philadelphia, USA)

    Objective: To determine the functional consequences of baseline anxiety symptoms and the longer-term impact of initiation of anxiety treatment in Parkinson’s disease (PD). Background: While…
  • 2023 International Congress

    Healthcare experiences of People with Parkinson’s Disease (PwP) during COVID-19 pandemic

    V. Tomantschger, A. Tautscher-Basnett, C. Hohenwarter (Hermagor, Austria)

    Objective: To investigate how our group of PwP coped with healthcare issues during the pandemic. Background: COVID-19 pandemic led to changes in how healthcare services…
  • 2023 International Congress

    Dynamic assessment of levels of depression and anxiety impairment in Parkinson’s disease

    O. Naimov, R. Matmurodov (Tashkent, Uzbekistan)

    Objective: To dynamic assessment of depression and anxiety disorders in Parkinson's disease. Background: One of the most common nonmotor disturbances in Parkinson's disease (PD) is…
  • 2023 International Congress

    Recruitment of Parkinson’s disease patients with mild-to-moderate anxiety into a randomized controlled trial: Experience of a large Canadian tertiary movement disorders clinic

    J. Lam, J. Zhu, D. Meng, P. Uzelman, S. Appel-Cresswell (Vancouver, Canada)

    Objective: To report our experience of recruiting Parkinson’s disease (PD) patients with mild-to-moderate anxiety into a randomized controlled trial. Background: Anxiety is a common non-motor…
  • 2023 International Congress

    Longitudinal assessment of evolution and plasma biomarkers for depression and anxiety in Parkinson’s disease

    J. Lin, R. Ou, C. Li, Q. Wei, Y. Hou, L. Zhang, K. Liu, Q. Jiang, T. Yang, Y. Xiao, D. Pang, Y. Yu, B. Zhao, X. Chen, W. Song, J. Yang, Y. Wu, H. Shang (Chengdu, China)

    Objective: We aimed to investigatethe evolution of depression and anxietyin a large Parkinson's disease (PD) cohort and explore the related plasma biomarkers. Background: Depression and anxietyare common non-motor…
  • 2023 International Congress

    Association between type 2 diabetes mellitus with parkinson’s disease and the increase of the severity of depression and anxiety in a mexican population

    AA. Herrera Ruiz, DR. Aguila Godinez, AJ. Hernández-Medrano, MA. Ruiz Mafud, A. Abundes-Corona, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)

    Objective: To compare the severity of depression and anxiety in PwP between those with T2D and those without T2D. Background: Parkinson's disease (PD) is the…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • #24475 (not found)
  • Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley